3-Chloro-4-(pyridin-3-yl)-1,2,5-thiadiazole, with CAS number 131986-28-2, is a high-purity heterocyclic building block. It is globally recognized as the key strategic intermediate for the synthesis of Xanomeline (the active component of the blockbuster schizophrenia drug KarXT/Cobenfy). As a professional supplier, we provide commercial-scale supply with rigorous quality control to support the booming demand in the neurological drug market.
Product Name :
3-Chloro-4-(pyridin-3-yl)-1,2,5-thiadiazole CAS 131986-28-2CAS No. :
131986-28-2Application :
Xanomeline IntermediatesDudley's 3-chloro-4-(pyridin-3-yl)-1,2,5-thiadiazole is a high-purity heterocyclic pharmaceutical intermediate, appearing as a white to cream-colored crystalline powder. As a key starting material for the synthesis of muscarinic acetylcholine receptor (mAChR) agonists (such as Xanomeline), this product holds a strategically vital position in the development of new drugs for the treatment of schizophrenia and Alzheimer's disease. We employ advanced cyclization and chlorination processes, rigorously controlling impurity levels to ensure that we provide our global customers with high-quality intermediates that meet drug registration requirements.
Properties
- Appearance: white solid
- Melting Point: 50-57 °C
- Boiling Point: 297.2±25.0 °C
- Density: 1.455±0.06 g/cm³
- Solubility: Soluble in dichloromethane, ethyl acetate, and methanol; slightly soluble in water.
- Storage temp:2-8°C
Specification
| Items | Specifications |
| Appearance | white solid |
| Purity | 99%min |
| Waler Content | ≤ 0.1% |
| The single biggest unknown impurity | ≤ 0.15% |
Applications
3-Chloro-4-(pyridin-3-yl)-1,2,5-thiadiazole (CAS: 131986-28-2) is a core building block for constructing thiadiazole bioactive molecules, and is widely used, especially in the synthesis of drugs for the nervous system.
This is the highest-value application of the product. It is the core precursor for the synthesis of the M1/M4 muscarinic receptor agonist Xanomeline. Market demand for this intermediate is exploding following FDA approval of KarXT (Cobenfy) for the treatment of schizophrenia.
The active pharmaceutical ingredient can be efficiently synthesized via nucleophilic substitution (introducing an alkoxy side chain) and reductive/methylation modification of the pyridine ring.
FP-TZTP is used to synthesize a PET imaging agent for studying the distribution and function of muscarinic receptors in the brain.
The chlorine atom at the 3-position exhibits good reactivity and can undergo Suzuki coupling or nucleophilic substitution reactions, enabling the construction of a diverse library of 3,4-disubstituted-1,2,5-thiadiazole derivatives.
Package

leave a message
Scan to wechat :
Scan to whatsapp :